Interesting EngineeringBill Gates Says We Need to Embrace CRISPR Gene-Editing for Global DevelopmentInteresting EngineeringMicrosoft founder, Bill Gates has come out as an ardent supporter of gene editing technology. Gates who now runs the Bill & … Continue reading
CNBCA new, personalized vaccine is targeting the deadliest cancers in AmericaCNBCNew vaccines, targeting the most deadly forms of cancer in the United States, are undergoing trials across the country and being heralded as promising breakthroughs in the… Continue reading
Kaiser Health NewsCRISPR Has Made Its Way Into Popular Culture. How Accurate Is …Kaiser Health News"Rampage" is the latest movie to feature CRISPR as a plot device. Stat takes a look at what it gets right and wrong. In other public health n… Continue reading
World Synthetic Biology Workstation Market Key Players, Trends …Pharmaceuticals NewsSynthetic Biology Workstation Market Research report 2018-2022 offers a unique tool for evaluating the market, New Opportunities and supporting strategies. Synthetic … Continue reading
Business Wire (press release) |
Pfizer Doses First Patient Using Investigational Mini-Dystrophin …
Business Wire (press release) NEW YORK–(BUSINESS WIRE)–Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene … Pfizer Begins Clinical Trial With Mini-dystrophin Gene Therapy CandidateNasdaq Pfizer (PFE) Commences Phase 1b Clinical Trial for Investigational …StreetInsider.com First Duchenne Patient Dosed in Pfizer’s Mini-Dystrophin StudyRare Disease Report |
Immuno-Oncology News |
Society of Interventional Oncology and BTG Award Five Cancer Research Grants
Immuno-Oncology News The Society of Interventional Oncology (SIO) and the therapy development company BTG have chosen five winners of this year’s Immuno-Oncology/Interventional Oncology research grants. They founded the program in 2017 to fund cutting-edge immunotherapy … |
Xconomy |
As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal
Xconomy Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn’t yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market but has struggled to sell it, is … GSK sells rare disease gene therapy portfolio – Financial TimesFinancial Times GSK slims portfolio with sale of rare disease gene therapy drugsReuters UK gene therapy firm Orchard plans stock offer after GSK dealWHTC GlobeNewswire (press release) –Genetic Engineering & Biotechnology News –Zacks all 110 news articles » |